利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.053 秒)

    Antibodies to M-CSF
    2.
    发明申请
    Antibodies to M-CSF 有权
    M-CSF抗体

    公开(公告)号：US20050059113A1

    公开(公告)日：2005-03-17

    申请号：US10938353

    申请日：2004-09-09

    申请人： Vahe Bedian ,  Madhav Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimee Kellermann ,  Joseph Low ,  James Mobley

    发明人： Vahe Bedian ,  Madhav Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimee Kellermann ,  Joseph Low ,  James Mobley

    IPC分类号： A61P29/00 ,  A61P35/00 ,  C07K16/24 ,  G06F20060101 ,  G06Q30/00 ,  C07H21/04 ,  C12N5/06

    CPC分类号： C07K16/243 ,  A61K38/193 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/24 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G06Q30/02 ,  G06Q30/0601 ,  G06Q40/04 ,  G06Q50/12 ,  Y02A50/412

    摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

    摘要翻译： 本发明涉及特异性结合M-CSF，优选人M-CSF的抗体及其抗原结合部分，其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。

    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION
    6.
    发明申请
    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION 失效
    通过V基因操作降低人类抗体抗体的风险

    公开(公告)号：US20100028906A1

    公开(公告)日：2010-02-04

    申请号：US12577696

    申请日：2009-10-12

    申请人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    发明人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    IPC分类号： G01N33/53 ,  A01K67/027

    CPC分类号： G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    摘要： The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

    摘要翻译： 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。

    Reducing the risk of human anti-human antibodies through V gene manipulation
    9.
    发明授权
    Reducing the risk of human anti-human antibodies through V gene manipulation 失效
    通过V基因操作降低人抗人抗体的风险

    公开(公告)号：US08198508B2

    公开(公告)日：2012-06-12

    申请号：US12577696

    申请日：2009-10-12

    申请人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    发明人： Sirid-Aimee Kellermann ,  Larry L. Green ,  Wouter Korver

    IPC分类号： A01K67/00 ,  A01K67/027 ,  A61K49/00

    CPC分类号： G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    摘要： The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included. Some embodiments herein are directed to transgenic mouse embodiments relevant for HAHA responses.

    摘要翻译： 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。 本文的一些实施方案涉及与HAHA反应相关的转基因小鼠实施方案。